ADMA
ADMA Biologics Inc
NASDAQ: ADMA · HEALTHCARE · BIOTECHNOLOGY
$8.75
+0.34% today
Updated 2026-06-26
Market cap
$2.02B
P/E ratio
12.82
P/S ratio
3.96x
EPS (TTM)
$0.68
Dividend yield
—
52W range
$7 – $20
Volume
5.4M
ADMA Biologics Inc (ADMA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$8.75
12-Month target
$9.58
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.1B | $0.2B | $0.3B | $0.4B | $0.5B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 12.82x (capped 25x) · Margin: 32.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.